Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • A4250: Phase IIa started

    Albireo AB, Gothenburg, Sweden Product: A4250 Business: Hepatic Molecular target: Solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2) (ASBT) (IBAT) Description: Inhibitor of solute carrier…

    Published on 2/23/2015
  • APL-2: Phase I started

    Apellis Pharmaceuticals Inc., Crestwood, Ky. Product: APL-2 Business: Ophthalmic Molecular target: Complement 3 (C3) Description: Complement 3 (C3) inhibitor Indication: Treat wet age-related macular degeneration (AMD) …

    Published on 2/23/2015
  • Betrixaban: Phase III ongoing

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Product: Betrixaban (PRT054021) Business: Cardiovascular Molecular target: Factor Xa Description: Oral Factor Xa inhibitor Indication: Hospital and…

    Published on 2/23/2015
  • cAd-EBOZ: Phase II/III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: cAd-EBOZ Business: Infectious Molecular target: NA Description: Recombinant chimpanzee adenovirus type 3 (cAd3) vector containing segments of genetic …

    Published on 2/23/2015
  • Ganaxolone: Phase II started

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), Radnor, Pa. Product: Ganaxolone (CCD-1042) Business: Neurology Molecular target: GABA A receptor Description: Synthetic neurosteroid and derivative of allopregnanolone, a GABA…

    Published on 2/23/2015
  • GLA-SE: Phase I started

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: GLA-SE (G100) (formerly GL-100, ID-G100) Business: Cancer Molecular target: Toll-like receptor 4 (TLR4) Description: Toll-like receptor 4 (TLR4) agonist …

    Published on 2/23/2015
  • HVTN 100: Phase I/II started

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: HVTN 100 Business: Infectious Molecular target: NA Description: Combination of Alvac-HIV (vCP205), a live …

    Published on 2/23/2015
  • Luveniq voclosporin: Pilot trial started

    3SBio Inc., Shenyang, China Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH), Victoria, B.C. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Product: Luveniq voclosporin (LX211) Business: Autoimmune …

    Published on 2/23/2015
  • MEDI4893: Phase II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4893 Business: Infectious Molecular target: NA Description: mAb targeting a Staphylococcus aureus toxin Indication: Prevent pneumonia caused by …

    Published on 2/23/2015
  • Reolysin: Completed Phase II enrollment

    Andrus Reo Ltd., Moscow, Russia Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta Product: Reolysin Business: Cancer Molecular target: Not applicable Description: Formulation of human reovirus type 3 …

    Published on 2/23/2015
  • RVSV-EBOV: Phase II/III started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: RVSV-EBOV, VSV-ZEBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular …

    Published on 2/23/2015
  • TAK-361S: Development discontinued

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: TAK-361S Business: Infectious Molecular target: NA Description: Tetravalent vaccine against diphtheria, tetanus, pertussis and polio Indication: Prevent…

    Published on 2/23/2015
  • TBA-354: Phase I started

    Global Alliance for TB Drug Development, New York, N.Y. Product: TBA-354 Business: Infectious Molecular target: NA Description: Next-generation nitroimidazole Indication: Treat tuberculosis (TB) Endpoint: Safety; …

    Published on 2/23/2015
  • VT-1161: Phase IIb started

    Viamet Pharmaceuticals Inc., Durham, N.C. Product: VT-1161 Business: Infectious Molecular target: Cytochrome P450 C-14 alpha demethylase (CYP51) Description: Oral small molecule inhibitor of fungal cytochrome P450 C-14 …

    Published on 2/23/2015
  • ABX464: Phase IIa started

    Abivax S.A.S., Paris, France Product: ABX464 Business: Infectious Molecular target: NA Description: Small molecule inhibitor of HIV replication Indication: Treat HIV infection Endpoint: Safety, viral load and change in …

    Published on 2/16/2015
  • Anatabine citrate: Phase I start

    Rock Creek Pharmaceuticals Inc. (NASDAQ:RCPI), Sarasota, Fla. Product: Anatabine citrate (RCP-006) Business: Inflammation Molecular target: NA Description: Small molecule cholinergic agonist Indication: Treat chronic …

    Published on 2/16/2015
  • BBI-4000: Phase IIb started

    Brickell Biotech Inc., Miami, Fla. Product: BBI-4000 Business: Other Molecular target: NA Description: Topical soft anticholinergic Indication: Treat primary axillary hyperhidrosis Endpoint: Proportion of patients …

    Published on 2/16/2015
  • Cytori Cell Therapy adipose-derived regenerative cells: Phase I started

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Cytori Cell Therapy adipose-derived regenerative cells (ADRCs) Business: Musculoskeletal Molecular target: Not available Description: …

    Published on 2/16/2015
  • Elsiglutide: Phase IIb started

    Helsinn Healthcare S.A., Lugano, Switzerland Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Elsiglutide (ZP1846) Business: Gastrointestinal Molecular target: Glucagon-like peptide-2 receptor (GLP-2R) …

    Published on 2/16/2015
  • F17464: Phase IIa started

    Pierre Fabre Group, Castres, France Product: F17464 Business: Neurology Molecular target: Dopamine D3 receptor (DRD3); Serotonin (5-HT1A) receptor Description: An oral selective dopamine D3 receptor (DRD3) antagonist …

    Published on 2/16/2015
  • FRM-0334: Phase IIa started

    Forum Pharmaceuticals Inc., Watertown, Mass. Product: FRM-0334 (formerly EVP-0334) Business: Neurology Molecular target: Histone deacetylase (HDAC) Description: Small molecule histone deacetylase (HDAC) inhibitor …

    Published on 2/16/2015
  • GSK2831781: Phase I started

    Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK2831781 Business: Autoimmune Molecular target: Lymphocyte-activation gene 3 (LAG3) (CD223) …

    Published on 2/16/2015
  • HTX-011: Phase I started

    Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: HTX-011 Business: Neurology Molecular target: NA Description: Combination of the local anesthetic bupivacaine and the anti-inflammatory meloxicam in …

    Published on 2/16/2015
  • Liposomal Grb-2: Phase II started

    Bio-Path Holdings Inc. (NASDAQ:BPTH), Houston, Texas Product: Liposomal Grb-2 (BP-100-1.01) Business: Cancer Molecular target: Growth factor receptor-bound protein 2 (GRB2) Description: Liposomal antisense inhibitor of …

    Published on 2/16/2015
  • Masican masitinib: Phase III ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masican masitinib (AB1010) Business: Neurology Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor…

    Published on 2/16/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993